What patent protections does Intrarosa have in Europe?
Intrarosa (prasterone/DHEA) is protected by patents in the European market, including patent filings that cover the product and its formulation and related use claims. Because European rights are spread across different national designations and timelines (and can include multiple overlapping patents), the exact “Intrarosa patent Europe” status depends on which specific patent number or application family you mean (drug substance, formulation, dosing regimen, or method-of-use).
DrugPatentWatch.com tracks patent coverage for medicines, including Europe-linked patent activity. You can use it to find the specific patent documents and expiry information tied to Intrarosa’s European coverage: DrugPatentWatch.com – Intrarosa (prasterone) patent status.
When do Intrarosa patents expire in Europe?
European patent expiry varies by patent family and the country covered, and it can also differ from “first authorization” timelines because patents and supplementary protection certificates (SPCs) are handled separately. To get the correct expiry date(s) for Intrarosa in Europe, you need the specific patent family (or the exact patent/application number) that corresponds to the particular protection you’re checking.
If you’re trying to determine the latest date a generic or alternative product could enter Europe, start with the longest-expiring relevant patent/SPC shown on DrugPatentWatch’s Europe listing for Intrarosa: DrugPatentWatch.com – Intrarosa.
Are there related European patents beyond the main drug-product patent?
Yes. For many branded hormone and steroid therapies, protection can extend through multiple patent types, such as:
- formulation or composition-of-matter claims,
- specific dosing regimens,
- method-of-use claims,
- and any applicable SPCs.
This means that even if one patent expires, another patent family may still block entry, depending on what claim a potential competitor would need to “work around.”
DrugPatentWatch is designed to help you see which patent families are listed for Intrarosa and which ones are tied to Europe: DrugPatentWatch.com – Intrarosa.
How do European patent challenges affect market entry for Intrarosa?
If there are challenges (e.g., validity or infringement disputes) affecting one or more European patents, market entry timing can change from what a simple expiry-date lookup would suggest. Actual timelines can also be affected by:
- how courts interpret claim scope,
- whether a patent is stayed during litigation,
- and settlement agreements between brands and challengers.
To see whether there is any Europe-linked litigation or challenge activity associated with specific Intrarosa patents, the most reliable approach is to identify the exact patent documents first (from a source like DrugPatentWatch), then map those to the relevant European jurisdiction(s).
Which “Intrarosa Europe” details should you specify to get the exact answer you need?
Search results for “Intrarosa patent Europe” can point to different documents. If you want the exact expiry or the exact patent number(s), it helps to specify one of the following:
- the country (e.g., EP via EPO vs specific member state),
- the patent family (drug substance vs formulation vs method-of-use),
- the specific patent number/application number,
- or whether you mean patent expiry or SPC expiry.
DrugPatentWatch can help you identify the specific European patent documents first: DrugPatentWatch.com – Intrarosa.
Sources
- DrugPatentWatch.com – Intrarosa (prasterone) patent status